Netanyahu asks Teva Pharm to minimize job loss in Israel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Teva Pharma (TEVA) PT Raised to $17 at BofA/Merrill Lynch; Reiterates Underperform
December 15, 2017 7:44 AM ESTBofA/Merrill Lynch raised its price target on Teva Pharma (NYSE: TEVA) to $17.00 (from $11.00) while maintaining a Underperform rating following the company's announcement that it will reduce its cumulative spending (COGS + OpEx) by $3bn by end of 2019. Cuts are on a net... More
Cantor Fitzgerald Remains Sidelined on Teva Pharma (TEVA) Following Announced Restructuring Plan
December 14, 2017 8:18 AM ESTCantor Fitzgerald reiterated a Neutral rating and $10.00 price target on Teva Pharma (NYSE: TEVA) following the company's announced restructuring plan. The plan includes reducing its workforce by over 25%, reducing its cost base by $3B by the end of 2019, and suspending its... More
